For example, results from the CheckMate 370 study (NCT02574078) study showed that combination of crizotinib, the first generation of ALK inhibitor, with nivolumab at the respective doses of 250mg twice daily and 240mg every two weeks appeared to exhibit some severe toxicities in advanced ALK-rearranged NSCLC patients [56]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.